# Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

> **NCT04672005** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lyudmyla Berim** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Folfirinox alternating with Gemcitabine-nab-Paclitaxel

## Key facts

- **NCT ID:** NCT04672005
- **Lead sponsor:** Lyudmyla Berim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-06
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672005, "Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04672005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*